輝瑞(PFE.US)削全年收入預測13% 減35億美元開支 涉及裁員
輝瑞(PFE.US)削減全年收入預測13%,並基於新冠疫苗及治療銷售遜預期,將削減35億美元工作及開支。
公司今年收入預測介乎580億至610億美元,低於原來預測的介乎670億至700億美元。下調預期單純基於新冠產品預期下調。公司亦在第三季錄得55億美元減值,包括46億美元新冠治療藥Paxlovid減值,以及9億美元庫存減值和其他疫苗支出。
公司計劃2024年底前削減最少35億美元開支,包括裁員,涉及削減開支的一次性成本料約30億美元。
輝瑞在上周五(13日)延長交易時段跌3.7%報30.92美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.